Ani Pharmaceuticals (ANIP) Other Accumulated Expenses (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Other Accumulated Expenses data on file, last reported at $33.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 43.07% year-over-year to $33.9 million; the trailing twelve-month figure through Mar 2026 stood at $33.9 million (up 43.07% YoY), and the FY2025 full-year result was $48.5 million, up 114.34% from the prior year.
• Other Accumulated Expenses declined to $33.9 million in Q1 2026, from $48.5 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $51.2 million in Q3 2025 to a low of $5.0 million in Q1 2022.
• A 5-year average of $20.6 million and a median of $16.3 million in 2023 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses decreased 5.88% in 2022 and jumped 118.57% in 2025, its largest moves.
• Tracing ANIP's Other Accumulated Expenses over 5 years: stood at $9.3 million in 2022, then surged by 74.88% to $16.3 million in 2023, then jumped by 39.01% to $22.6 million in 2024, then surged by 114.34% to $48.5 million in 2025, then tumbled by 30.05% to $33.9 million in 2026.
• Business Quant data shows ANIP's Other Accumulated Expenses at $33.9 million in Q1 2026, $48.5 million in Q4 2025, and $51.2 million in Q3 2025.